Home › NCT04755764

Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by ICG in Early Pregnancy

The Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by Impedance Cardiography in Early Pregnancy

Who can join

Ages 18 to 45 · Women · Healthy volunteers welcome

Inclusion Criteria:

* Patients presenting to Maternal Hypertension Center at Cabell Huntington Hospital
* English speaking
* 18-45 years old.
* Willing to provide informed consent
* Gestational age prior to 15 weeks gestation

Exclusion Criteria:

* Non-English speaking patients, patients
* \<18 years old or \>45 years old
* Not willing or able to provide consent
* Gestational age \>15 weeks

About the study

The purpose of the research is to characterize the effect of labetalol, atenolol, and nifedipine on maternal hemodynamics early in pregnancy. Patients will be given medication based on their hemodynamics and asked to return for a repeat measurement.

What is being tested

• Labetalol (drug)
• Atenolol (drug)
• Nifedipine (drug)

Sponsor: Marshall University · Participants: 60 · Started: Mar 3, 2021

Contact the study team

• Morgan Ruley, MS · Phone: (304) 691-1458
• Jesse Cottrell, MD · Phone: (304) 691-1400

Official record on ClinicalTrials.gov — NCT04755764

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.